Signify Premium Insight: Volpara Acquires CRA Health in $22m Deal

The trend towards the increasing personalisation of cancer screening gathered pace in early February when Volpara Health announced it had acquired breast cancer risk assessment company CRA Health.

The $22m deal will see Volpara take on all outstanding equity of CRA for $18m, with the remaining $4m payable upon CRA meeting certain performance targets over the next 18 months, and will add to Volpara’s broadening capability.

Vendor Impact

• The move to risk-based screening is gathering pace. Vendors which fail to acknowledge and adapt to this trend risk losing relevancy.
• AI market leaders, with well rounded, clinically useful solutions are starting to emerge. Smaller companies, selling narrow algorithms of comparatively limited clinical use look to be in an increasingly tenuous position.